Use when explaining or planning around AAAI's two-phase review process, Phase 1 rejection risk, Phase 2 additional reviews, AI-assisted review pilot, author feedback, SPC/AC discussion, and final decisions.
中文简介正在准备中。当前显示原文说明。
查看安装方法安装前可以查看交给 AI 代理的指令内容。
Use this to plan around AAAI review rather than treating it as a generic OpenReview rebuttal. Reopen the current review-process page and author FAQ before advising on timing or strategy.
AAAI's pipeline differs from a single-round OpenReview venue, so plan actions per stage rather than treating every signal as a rebuttal opportunity.
| Stage | What is happening | Author leverage |
|---|---|---|
| Pre-submission | Phase-1 bar is set by clarity and checklist | maximal: fix the paper itself |
| Phase 1 | human reviews plus advisory AI review | none yet; summary reject possible |
| Phase 2 | additional reviews, one feedback round | one short response, no new results |
| Discussion | reviewers and SPC/AC weigh feedback | indirect: a clean correction can swing it |
| Decision | SPC/AC oversight, not the AI review | archive everything for appeal or journal |
Because the reviewer pool is large and submission volume is high, clearly-below-bar papers are cut early to protect later effort. Common triggers: an unreadable first page, a contribution a non-specialist cannot place, a checklist that contradicts the paper, or evidence too thin to trust. None of these can be repaired after the Phase-1 cut, so they must be eliminated before submission.
An NLP paper with strong results buries its contribution under three pages of setup. A Phase-1 reviewer from a planning background cannot find the AI claim and scores it a reject; the paper never reaches feedback. The fix belongs entirely pre-submission: a first-page contribution statement and a checklist that matches the experiments, so the broad-AI reviewer can place and trust it fast.
[Stage] pre-submission / Phase 1 / Phase 2 / rebuttal / discussion / decision
[Decision risk] summary reject / borderline / likely accept / ethics-policy risk
[Best action] revise before submission / rebut / clarify evidence / escalate
[AI-review handling] ignore / correct / cite submitted evidence
[Rationale] <why this fits AAAI process>
还没有评价。欢迎分享你的使用感受。
无需登录即可发表。欢迎分享使用感受、提问，或说明在哪些环境下无法运行。
还没有评论。来写第一条吧。
Use when packaging AAAI code, data, multimedia appendices, technical appendices, reproducibility evidence, and post-acceptance artifact releases without violating double-blind or immutable-supplement rules.
中文简介正在准备中。当前显示原文说明。
Use when drafting an AAAI author response (rebuttal) under the single short character-limited author-feedback window, the no-URL rule, no-new-results guidance, AI-generated-review handling, and the AAAI two-phase review process where Phase-2 papers receive one feedback round before SPC/AC discussion.
中文简介正在准备中。当前显示原文说明。
Use when preparing an accepted AAAI paper for camera-ready source submission to AAAI Press, including proceedings page limits, two-column template compliance, copyright transfer, purchased extra technical pages, deanonymization, registration, oral or poster presentation, and final public artifact release.
中文简介正在准备中。当前显示原文说明。
Use when designing or auditing AAAI experiments for the broad-AI program committee, including baselines, ablations, statistical significance, robustness, human evaluation, AI-for-Social-Impact and alignment/safety evidence, compute and cost reporting, and reproducibility-checklist alignment for Phase-1 survival.
中文简介正在准备中。当前显示原文说明。
Use when positioning an AAAI paper's novelty against archival work, contemporaneous arXiv or workshop papers, and AAAI/IJCAI/NeurIPS/ICML/ICLR neighbors across the broad AI scope, while staying inside AAAI's dual-submission and AI-as-source policy constraints and writing a related-work section legible to non-specialist reviewers.
中文简介正在准备中。当前显示原文说明。
Use when strengthening an AAAI paper's reproducibility checklist (placed after references), experimental traceability, seed and hyperparameter reporting, compute and cost disclosure, dataset access and licensing, code/data ZIP readiness, and the claim-to-evidence map that Phase-1 reviewers use to judge rigor across AAAI's broad AI scope.
中文简介正在准备中。当前显示原文说明。